A powerful, unsolicited validation for Cereno's drug came when Phase 2a investigators asked to continue treating patients post-trial. Securing FDA approval for compassionate use demonstrated strong physician conviction and provided valuable long-term safety and tolerability data.

Unlike vaccines requiring a patient's immune system to generate antibodies, Cidara's CD388 is a long-acting antiviral drug. It provides direct, passive protection by targeting a non-mutating part of the flu virus, making it effective for the millions of people with weakened immune systems who don't respond well to traditional shots.

CervoMed first secured FDA alignment on its Phase III trial design. It then presented this solidified plan to European and Japanese regulators, which creates a single, consistent global protocol that saves time, money, and avoids market confusion from different labels.

Corvus Pharmaceuticals' ITK inhibitor received FDA encouragement to proceed directly from Phase 1 to a Phase 3 registrational trial for T-cell lymphoma. This was due to the disease's high mortality, lack of effective treatments, and the drug's exceptionally strong early survival data.

The FDA is abandoning rigid, fixed-length clinical trials for a "continuous" model. Using AI and Bayesian statistics, regulators can monitor data in real-time and approve a drug the moment efficacy is proven, rather than waiting for an arbitrary end date, accelerating access for patients.

The FDA's justification for rejection hinges on the vaccine's trial design for the 65+ population. Traditionally, the FDA grants broad approval, and the CDC's ACIP makes specific usage recommendations. The FDA is now blurring these lines, pre-judging post-market public health guidance.

Despite FDA readiness for a final Phase 3 trial, Connect Biopharma chose to run more Phase 2 studies. They discovered their long-term asthma drug worked in hours, not weeks, and are now pivoting to prove its value in acute, emergency situations, which informs a stronger, more targeted Phase 3 design.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.

An unexpectedly severe flu season, the worst in 15 years, created ideal conditions for Cidara's Phase 2b clinical trial. The high infection rate allowed the 5,000-participant study to demonstrate statistically significant efficacy, an outcome researchers hadn't anticipated would be possible at that stage of development.